Lilly Bets $8B on Weight Loss Future

GLP-1 Showdown: Inside The High Stakes War over Patients

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for. In this episode, we break down Novo Nordisk’s lawsuit accusing Eli Lilly of misleading patients through advertisements comparing Zepbound and Mounjaro with Wegovy and Ozempic. The fight is not simply about which medication produces more weight loss. It is about who controls the information patients receive, which evidence gets highlighted, and what gets left in the fine print. Then we examine STAT News’ investigation into LifeMD, a major telehealth company promoted by Novo as a legitimate pathway to GLP-1 treatment. Former employees alleged providers were pushed to process patients at breakneck speed, sometimes reviewing as many as 25 cases per hour, while refill queues, dose increases and patient messages piled up. LifeMD strongly disputes those allegations. But this cannot become another simplistic story about telehealth being bad. More than 100 million Americans are living with obesity, and only a small number of clinicians have dedicated obesity medicine expertise. The traditional healthcare system does not have enough specialists, appointment slots or geographic reach to provide every patient with an ideal, hour-long consultation. So how altruistic can we afford to be about access? Can we demand a perfect standard of care that most patients will never be able to reach? Or does scaling treatment too aggressively risk turning patients into transactions inside a prescription machine? Access cannot become a shield for negligence. But perfection cannot become another form of gatekeeping. The patient is being fought over. This episode asks what it would actually mean to fight for them. Learn more and follow On The Pen: https://www.otplinks.com This episode is sponsored by VoaFit, where I receive care for obesity and metabolic health. https://www.voafit.com/otp to learn more!

Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know

What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity treatment. In this week's On The Pen Podcast, we're breaking down one of the biggest shifts happening in obesity medicine. We dive into new research on GLP-1 persistence, the early challenges facing Medicare's obesity drug rollout, and why pharmaceutical companies are racing to solve the problems patients have been talking about for years. We also discuss the next generation of obesity therapies, including oral GLP-1s, implantable medications, muscle-preserving treatments, and why the future of obesity medicine may be less about losing more weight and more about helping patients stay healthy for the long term. In this episode: • Why patients who stop GLP-1 therapy often return • The first weeks of Medicare's obesity medication coverage • The future of oral GLP-1 medications • New implant technology from Novo Nordisk • Muscle-preserving obesity treatments • Why patient experience is becoming the next frontier in obesity medicine The goal of On The Pen has always been simple: translate complex obesity and diabetes news into information that helps you have better conversations with your doctor. 👇 What has been your biggest obstacle to staying on treatment? Insurance? Cost? Side effects? Tell us in the comments. 📰 Read more obesity medicine news: https://OnThePen.com [https://onthepen.com/] 📩 Subscribe to my free newsletter: https://obesity.news [https://obesity.news/] 🔗 All my links: https://OTPLINKS.com [https://linktr.ee/manonthemounjaro] 👍 If you found this helpful, please Like, Subscribe, and Share this episode with someone navigating obesity, diabetes, or GLP-1 treatment. #GLP1 #Obesity #WeightLoss #Zepbound #Mounjaro #Ozempic #Wegovy #ObesityMedicine #Type2Diabetes #OnThePen #Healthcare #Medicare #Podcast

Compound GLP-1 Poll STUNS THE INTERNET!

What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to do with the drug itself, and everything to do with the patient experience. ALL OUR LINKS: http://www.otplinks.com HEADLINE SPONSOR LINK: https://www.voafit.com/otp ACCOMODATIONS BY: https://thepixellab.co

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America. We discuss: ✅ Medicare Bridge Program eligibility requirements ✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates ✅ BMI and comorbidity qualifications ✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access ✅ How Medicare patients can obtain GLP-1 medications ✅ Why obesity is finally being treated as a chronic disease ✅ The future of obesity medicine and Medicare coverage ✅ Concerns about access to care vs access to medication ✅ Muscle loss, nutrition, strength training, and healthy weight loss ✅ The Treat and Reduce Obesity Act (TROA) This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care. 📖 Read more obesity medicine news at Obesity.News 🔗 All links: linktr.ee/manonthemounjaro #GLP1 #Medicare #Zepbound #Wegovy #Obesity #WeightLoss #ObesityMedicine #MedicareBridgeProgram #Tirzepatide #Semaglutide #Foundayo #Orforglipron #Prediabetes #Type2Diabetes #WeightManagement #AngelaFitch #OnThePen #MedicareCoverage #GLP1News #ObesityTreatment #HealthcarePolicy #WeightLossMedication #ChronicDisease #Mounjaro #Retatrutide #Lilly #NovoNordisk #ObesityAdvocacy #GLP1Community #MedicarePatients

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine. We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more! From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases? In this episode: ✅ Survodutide obesity and liver fat reduction data ✅ Mazdutide Phase 3 obesity and diabetes results ✅ UBT251 triple agonist weight loss data ✅ Berobenatide (MET-097) long-acting GLP-1 updates ✅ CagriSema diabetes and obesity trial results ✅ Zenagamtide (Amycretin) injectable and oral development ✅ Petrelintide amylin agonist info ✅ Future GLP-1, GIP, glucagon, and amylin therapies The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale. Read more obesity medicine news at obesity.news 🔗 Linktree: linktr.ee/manonthemounjaro #ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen